Pooled Analysis Comparing the Efficacy of Intracoronary vs. Intravenous Abciximab in Smokers Versus Non-Smokers undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction

Cigarette smokers with ST-segment elevation myocardial infarction (STEMI) may present different response to potent antithrombotic therapy compared with non-smokers. We assessed the impact of smoking status and intracoronary abciximab in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). We pooled data from 5 randomized trials comparing intracoronary versus intravenous abciximab bolus in patients undergoing primary PCI. The primary endpoint was the composite of death or reinfarction at a mean follow-up of 292 ±138 days.

Source: The American Journal of Cardiology - September 12, 2016 Category: Cardiology Authors: Raffaele Piccolo, Gennaro Galasso, Ingo Eitel, Alberto Dominguez-Rodriguez, Allan Zeeberg Iversen, Youlan L. Gu, Pedro Abreu-Gonzalez, Bart JGL. de Smet, Giovanni Esposito, Stephan Windecker, Holger Thiele, Federico Piscione Source Type: research